Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Testosterone transdermal - Acrux

Drug Profile

Testosterone transdermal - Acrux

Alternative Names: Luramist; Testosterone MDTS®; Testosterone transdermal spray - Acrux

Latest Information Update: 24 Jun 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acrux
  • Developer Acrux; Fempharm; Howard Florey Institute; National Health and Medical Research Council Clinical Trials Centre
  • Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone congener stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Female sexual dysfunction

Highest Development Phases

  • Discontinued Cognition disorders; Female sexual dysfunction

Most Recent Events

  • 06 Aug 2015 Discontinued - Phase-II for Female sexual dysfunction in Australia (Transdermal)
  • 23 Jan 2015 Biomarkers information updated
  • 10 Aug 2010 All rights to Luramist® belong to Fempharm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top